$PFE · Pfizer Inc.
Pfizer Inc. filed a Form 8-K reporting that its Board of Directors unanimously elected Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026. Ms. Guegan had been serving as Interim Chief Financial Officer since August 16, 2026. She has more than 25 years of global finance leadership in the pharmaceutical industry and joined Pfizer through its 2009 acquisition of Wyeth. Before becoming interim CFO, she was Senior Vice President of Finance for Pfizer’s Global Biopharmaceuticals business, a role she held since 2022.
The filing also details Ms. Guegan’s compensation arrangements approved by the Compensation Committee. Her annual base salary is set at $1,300,000, and her annual target cash incentive opportunity is $1,300,000, equal to 100% of her annual base salary. The filing includes a press release dated November 3, 2026, as an exhibit announcing the appointment.